Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F18%3A00078149" target="_blank" >RIV/00209805:_____/18:00078149 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/journal/physics-and-imaging-in-radiation-oncology" target="_blank" >https://www.sciencedirect.com/journal/physics-and-imaging-in-radiation-oncology</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.phro.2018.06.004" target="_blank" >10.1016/j.phro.2018.06.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas

Popis výsledku v původním jazyce

Background and purpose: The amino-acid positron emission tomography (PET) tracer 3,4-dihydroxy-6-[18F] fluoro-L-phenylalanine (18F-DOPA) has increased sensitivity for detecting regions of biologically aggressive tumors compared to T1 contrast-enhanced (T1-CE) magnetic resonance imaging (MRI). We performed dosimetric evaluation of treatment plans prepared with and without inclusion of 18F-DOPA-based biological target volume (BTV) evaluating its role in guiding radiotherapy of grade III/IV gliomas. Materials and methods: Eight patients (five T1-CE, three non-contrast-enhancing [NCE]) were included in our study. MRI only-guided anatomic plans and MRI+18FDOPA-PET-guided biologic plans were prepared for each patient, and dosimetric data for target volumes and organs at risk (OAR) were compared. High-dose BTV60Gy was defined as regions with tumor to normal brain (T/N)&gt;2.0, while low-dose BTV51Gy was initially based on T/ N&gt;1.3, but refined per Nuclear Medicine expert. Results: For T1-CE tumors, planning target volumes (PTV) were larger than MRI-only anatomic target volumes. Despite increases in size of both gross target volumes and PTV, with volumetric-modulated arc therapy planning, no increase of dose to OAR was observed while maintaining similar target dose coverage. For NCE tumors, MRI +18F-DOPA PET biologic imaging identified a sub-region of the large, T2-FLAIR abnormal signal which may allow a smaller volume to receive the high dose (60 Gy) radiation. Conclusions: For T1-CE tumors, PTVs were larger than MRI-only anatomic target volumes with no increase of dose to OARs. Therefore, MRI+18F-DOPA PET-based biologic treatment planning appears feasible in patients with high-grade gliomas. 1. Introduction Evidence has emerged for a role of metabolic or biologic imaging in gliomas [1-4]. The amino-acid positron emission tomography (PET) tracer 3,4-dihydroxy-6-[18F] fluoro-l-phenylalanine (18F-DOPA) was found to have considerably increased sensitivity for detecting regions of biologically aggressive tumors compared to T1 contrast-enhanced (T1-CE) magnetic resonance imaging (MRI). In addition, T1-CE substantially underestimated the volume of the highly aggressive disease components [4]. Utilizing a derived threshold (uptake ratio of tumor to contralateral normal brain&gt;2.0), high uptake regions were identified outside of T1-CE in 8 of the 21 patients in our previous pilot study, including 3 non-contrast-enhanced (NCE) patients [4]. Ledezma et

Název v anglickém jazyce

Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas

Popis výsledku anglicky

Background and purpose: The amino-acid positron emission tomography (PET) tracer 3,4-dihydroxy-6-[18F] fluoro-L-phenylalanine (18F-DOPA) has increased sensitivity for detecting regions of biologically aggressive tumors compared to T1 contrast-enhanced (T1-CE) magnetic resonance imaging (MRI). We performed dosimetric evaluation of treatment plans prepared with and without inclusion of 18F-DOPA-based biological target volume (BTV) evaluating its role in guiding radiotherapy of grade III/IV gliomas. Materials and methods: Eight patients (five T1-CE, three non-contrast-enhancing [NCE]) were included in our study. MRI only-guided anatomic plans and MRI+18FDOPA-PET-guided biologic plans were prepared for each patient, and dosimetric data for target volumes and organs at risk (OAR) were compared. High-dose BTV60Gy was defined as regions with tumor to normal brain (T/N)&gt;2.0, while low-dose BTV51Gy was initially based on T/ N&gt;1.3, but refined per Nuclear Medicine expert. Results: For T1-CE tumors, planning target volumes (PTV) were larger than MRI-only anatomic target volumes. Despite increases in size of both gross target volumes and PTV, with volumetric-modulated arc therapy planning, no increase of dose to OAR was observed while maintaining similar target dose coverage. For NCE tumors, MRI +18F-DOPA PET biologic imaging identified a sub-region of the large, T2-FLAIR abnormal signal which may allow a smaller volume to receive the high dose (60 Gy) radiation. Conclusions: For T1-CE tumors, PTVs were larger than MRI-only anatomic target volumes with no increase of dose to OARs. Therefore, MRI+18F-DOPA PET-based biologic treatment planning appears feasible in patients with high-grade gliomas. 1. Introduction Evidence has emerged for a role of metabolic or biologic imaging in gliomas [1-4]. The amino-acid positron emission tomography (PET) tracer 3,4-dihydroxy-6-[18F] fluoro-l-phenylalanine (18F-DOPA) was found to have considerably increased sensitivity for detecting regions of biologically aggressive tumors compared to T1 contrast-enhanced (T1-CE) magnetic resonance imaging (MRI). In addition, T1-CE substantially underestimated the volume of the highly aggressive disease components [4]. Utilizing a derived threshold (uptake ratio of tumor to contralateral normal brain&gt;2.0), high uptake regions were identified outside of T1-CE in 8 of the 21 patients in our previous pilot study, including 3 non-contrast-enhanced (NCE) patients [4]. Ledezma et

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Physics and Imaging in Radiation Oncology

ISSN

2405-6316

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

April

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

94-100

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85070485403